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Abstract 
Accurate diagnosis of predisposition to long QT syndrome is crucial for reducing the 
risk of cardiac arrhythmias. In recent years, drug-induced provocative tests have proved 
useful to unmask some latent mutations linked to cardiac arrhythmias. In this study we 
expanded this concept by developing a prototype for a computational provocative 
screening test to reveal genetic predisposition to acquired Long-QT Syndrome 
(aLTQS).   
We developed a computational approach to reveal the pharmacological properties of IKr 
blocking drugs that are most likely to cause aLQTS in the setting of subtle alterations in 
IKr channel gating that would be expected to result from benign genetic variants. We 
used the model to predict the most potentially lethal combinations of kinetic anomalies 
and drug properties. In doing so, we also implicitly predicted ideal inverse therapeutic 
properties of K channel openers that would be expected to remedy a specific defect. We 
systematically performed “in silico mutagenesis” by altering discrete kinetic transition 
rates of the Fink et al. Markov model of human IKr channels, corresponding to 
activation, inactivation, deactivation and recovery from inactivation of IKr channels.  We 
then screened and identified the properties of IKr blockers that caused acquired Long QT 
and therefore unmasked mutant phenotypes for mild, moderate and severe variants. 
Mutant IKr channels were incorporated into the O’Hara et al. human ventricular action 
potential (AP) model and subjected to simulated application of a wide variety of IKr-
drug interactions in order to identify the characteristics that selectively exacerbate the 
AP duration (APD) differences between wild-type and IKr mutated cells. Our results 
show that drugs with disparate affinities to conformation states of the IKr channel are 
key to amplify variants underlying susceptibility to acquired Long QT Syndrome, an 
effect that is especially pronounced at slow frequencies. Finally, we developed a 
mathematical formulation of the M54T MiRP1 latent mutation and simulated a 
provocative test. In this setting, application of dofetilide dramatically amplified the 
predicted QT interval duration in the M54T hMiRP1 mutation compared to wild-type. 
 
Keywords: mutations, drug-induced long-QT syndrome, drug-induced arrhythmias, 
computer modeling, potassium channels, genetics.  
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Abbreviations 
aLQTS: drug-induced or acquired long-QT syndrome 
AP: action potential 
APD: action potential duration   
APD90: action potential duration at 90% repolarization 
C1: closed state 1 
C2: closed state 2  
C3: closed state 3 
EAD: early-afterdepolarization 
ECG: electrocardiogram  
I: inactivated state 
IKr: rapid component of the delayed rectifier current 
LQTS: long-QT syndrome  
O: open state  
RFI: recovery from inactivation 
TdP: torsade de pointes 
WT: wild-type 
Actilide_Oc: drug binding simultaneously to both the open and closed states with lower 
affinity to the open state 
Inactilide_Oi: drug binding simultaneously to both the open and inactivated states with 
lower affinity to the open state 
Actilide_Co: drug binding simultaneously to both the closed and open states with lower 
affinity to the closed state 
Inactilide_Io: drug binding simultaneously to both the inactivated and open states with 
lower affinity to the inactivated state 
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1. Introduction  
Drug-induced or acquired long-QT syndrome (aLQTS) is a disorder characterized by 
abnormally prolonged ventricular repolarization secondary to drug application that can 
lead to potentially lethal arrhythmias, such as torsade de pointes (TdP) [1]. This side-
effect has resulted in black box warnings limiting the use of many drugs intended for 
treatment of cardiac dysrhythm, psychiatric disorders, gastrointestinal symptoms and 
infection [2] (http://www.qtdrugs.org).  Drugs have even been removed from the market 
due to unintended effects on cardiac repolarization [3].  
 
Because the rapidly activating component of the cardiac delayed rectifier current (IKr) 
arising from the gene hERG is a well-known promiscuous drug target, there has been 
deliberate focus on the off-target drug effects on hERG. Importantly, susceptibility to 
aLQTS has been linked to normally benign DNA variants in the genes encoding hERG 
and its ancillary subunits that modify risk to aLQTS and arrhythmias [1, 4, 5]. Indeed, 
approximately 15% of patients with aLQTS have been shown to exhibit allelic variants 
in coding regions of genes linked to congenital forms of long-QT syndrome (LQTS) [5]. 
 
Accurate identification of individuals who are susceptible to aLTQS is crucial for 
reducing the risk of cardiac arrhythmias [6]. Unfortunately, diagnosis based on baseline 
QT interval is not definitive [7] and genetic testing is difficult, expensive and is not 
always accessible [8]. In the last decade, drug-induced provocative tests have been 
proposed to unmask some types of latent mutation carriers. These provocative tests 
consist of the addition of a drug that uncovers an otherwise concealed disease. During 
the provocative test, the functional effects of a presumed defective ion channel are 
amplified, leading to measurable alterations in the electrocardiogram relative to changes 
observed with a normal channel. For example, catecholamines, such as epinephrine, can 
be used to reveal LQT1, which is due to IKs impairment [8], potent sodium blockers [9], 
such as flecainide, and also potent sodium blockers with calcium blockers [10] have 
been used to unmask Brugada Syndrome, and sotalol [11] and erythromycycin [12], 
potent IKr blockers, have been shown to uncover altered repolarization. 
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Here, we employed a mathematical modeling approach to take existing tests a step 
further. We attempt to reveal the pharmacological properties of IKr blocking drugs that 
not only reveal predisposition to aLQTS, but also reveal the specific kinetic anomaly 
underlying the increased risk. In doing so, we also implicitly predict ideal therapeutic 
properties of K+ channel openers that would be expected to remedy the defect. We 
systematically carried out “in silico mutagenesis” by altering discrete kinetic transition 
rates corresponding to activation, inactivation, deactivation and recovery from 
inactivation of IKr channels. Our model predicts the most potentially lethal combinations 
of kinetic abnormalities and drug properties. Moreover, it identifies the specific 
properties of an IKr blocker that most exacerbate mutant phenotypes arising from 
specific defective IKr kinetics (activation, deactivation, inactivation and recovery from 
inactivation). Such a test can be used to unmask the mutant phenotype for latent, mild, 
and moderate mutants. Importantly, our method consists of a library of “off-the-shelf” 
mutant and drug interaction templates that can be readily expanded to predict drug 
interactions with any identified IKr mutation. To apply our approach in a true clinical 
setting, we carried out an in silico screen for the naturally occurring hERG mutation, the 
M54T MiRP1 mutation, which has been implicated in drug-induced LQTS and 
arrhythmia. We used the model to propose a provocative test to unmask the M54T 
mutation, which the model predicts will be most successful with a drug binding 
simultaneously to both the open and closed states with lower affinity to the open state 
(Actilide_Oc) or a drug binding simultaneously to both the open and inactivated states 
with lower affinity to the open state (Inactilide_Oi), like dofetilide. We also predict that 
use of a potassium channel opener as an adjunctive therapy can effectively blunt the 
effects of dofetilide-induced action potential prolongation of the M54T hMiRP1 
mutation. Finally, the influence of heart rate and the concomitant effects of silent 
mutations in genes encoding other ionic currents were also investigated. 
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2. Methods 
The human ventricular IKr was simulated using the five-state Markov chain proposed by 
Fink et al. [13]. Transition rate constants are provided in the supplemental material 
(Table S1). The Fink IKr Markov model was incorporated into the O’Hara et al. human 
ventricular action potential (AP) model [14] and its maximum conductance was scaled 
to elicit the same peak IKr value as the original O’Hara model at 1Hz.  
 
Activation (αα), deactivation (), inactivation (αi) and recovery from inactivation (i) 
transition rates were modified to simulate genetic defects altering the activation, 
deactivation, inactivation and recovery from inactivation processes, respectively. In 
each case, transition rates were scaled to produce a 10 ms, 20 ms and 50 ms 
prolongation of action potential duration at 90% repolarization (APD90) at 1 Hz, which 
gives rise to 12 prototypical IKr mutations. Scale factors are provided in the 
supplemental material (Table S2). Moreover, additional summative effects of IKs and 
INaL silent mutations were simulated by modifying the slow component of the delayed 
rectifier current (IKs) and the late sodium current (INaL). IKs and INaL were independently 
scaled to produce a 20 ms APD90 prolongation in WT cells. Then, all possible IKr 
mutants were simulated alone or in addition to these IKs and INaL modifications to 
simulate the combined effects of IKr, IKs and INaL silent mutations. A total number of 38 
prototypical mutants, namely, 12 IKr mutations, 12 IKr mutations combined with IKs 
reduction, 12 IKr mutations combined with INaL increase, one IKs mutation alone and one 
INaL mutation alone, were simulated. 
 
The M54T hMiRP1 mutation was modeled using a modified Nelder-Mead Simplex 
Method to modify the Markov model transition rates in the Fink IKr model by 
minimizing the sum of the least-square errors between the experimental [4] and the 
simulated steady state activation curves, steady state inactivation curves and 
deactivation time constants. Then, to validate the M54T hMiRP1 mutation 
computational model, the simulated reduction of current density at -40 mV was 
compared to additional experimental results [1]. As experiments were performed at 
22ºC [4] and room temperature [1], temperature was exclusively fixed to 22ºC to 
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compare the simulated kinetics of the mutation to experiments. Physiological action 
potential simulations were subsequently performed at 37ºC. Rate transitions for WT and 
the mutated cells are available in the supplemental material (Table S1). 
 
In order to simulate known drug interactions with IKr, we used measured affinities and 
drug diffusion rates used to constrain the drug “on” and “off” rates.  Diffusion rates (D) 
indicate drug on rates “k” = [drug] * D and affinities (Kd) to discrete conformations that 
determine drug off rates “r” = Kd * D. Association (k) and dissociation (r) rate values 
for each IKr-drug interaction as tested in the model are in the supplement (Table S3). On 
and off rates were varied in simulations of “theoretical” drugs. A total number of 21 
drug interactions with IKr were simulated; dofetilide and 20 “theoretical drugs”. In 
addition, two potassium channel openers, RPR260243 and a virtually designed 
“activator” drug were simulated in some cases. In order to simulate the effects of 
RPR260243 we used the same binding and unbinding rate constants as Perry et al. [15] 
and activator bound channels were reconstructed applying the same modifications as 
Perry and coworkers to the WT channels, namely slowed deactivation, slowed 
activation and reduced inactivation [15]. The model of the virtual activator resulted 
from eliminating the reduced inactivation from the RPR260243 model and was called 
RPR260243_mod. 
 
1596 provocative tests were carried out with application of low and high concentrations 
of each simulated drug to WT cells and to every mutant at 1 Hz. For reproducibility, the 
low and high dose of a certain drug was defined as the drug concentration that produced 
the same steady state WT APD90 prolongation as 16 nM (in line with its therapeutic 
dose [3]) and 48 nM dofetilide, respectively. Low doses values for each simulated drug 
are available in the supplemental material (Table S3). 442 additional provocative tests 
were performed at 2 Hz and 0.67 Hz by applying low doses of those drugs that most 
amplified the effects of IKr mutants on ADP90 at 1 Hz to investigate the rate dependence 
of aLQTS in genetically predisposed cells. Furthermore, as APD adaptation to abrupt 
changes in pacing rate has been proposed as a clinical marker for arrhythmic risk [16], 
APD rate adaptation was also characterized by recording APD90 during the transition 
from the steady-state at 1Hz to 1.7 Hz and from 1.7 Hz to 1Hz after 10 minutes of 
pacing at 1.7 Hz. This protocol is similar to that used in clinical and experimental 
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studies [17, 18] and in other theoretical works [19, 20]. APD90 dynamics were 
characterized by the fast and slow time constants of the APD90 adaptation to the 
accelerating and decelerating rate transitions fast_accelerating,slow_accelerating,fast_decelerating 
andslow_decelerating, respectively) [19, 20]. When the duration of APD adaptation was 
longer than 10 minutes, independent prolongation of each transition was conducted to 
obtain the slow time constants. 
 
Action potential simulations were carried out in isolated endocardial cells at 1 Hz and 
pseudo-ECGs were computed using a 1-dimensional model of the transmural wedge 
preparation, as described in [14].  
 
3. Results 
We updated our previous dofetilide model [21] to additionally include the 
experimentally observed 70-fold preferential binding to the inactivated state relative to 
the open state [22] and to mimic the clinically observed 16 % prolongation of the QT 
interval produced by the therapeutic dose 8.22 nM [23] (summarized in Figure 1D). 
Figures 1 A-C show the kinetics of the simulated (lines) IKr block by 50 nM dofetilide 
(A and B) and the washout of 3 M (C) (solid lines) together with experimental results 
(symbols) for comparison: [24] (A), [25] (B) and [26](C). Protocols are described in 
[24-26]. Figures 1B and 1C show that our model also reproduces the experimentally 
observed voltage dependency of the onset of block by dofetilide [25] and the extremely 
slow and incomplete dissociation of dofetilide reported by many experimental works 
[24, 26, 27], respectively. To validate our simulations of drug interactions with IKr, the 
sensitivities of two hERG mutations, N588E and N588K, to IKr dofetilide block were 
also simulated. The N588E model was obtained by modifying the rates between the 
open and inactivated state to produce a – 36 mV shift of the conductance voltage curve 
(top panel of Figure 1E) and the N588K mutation model was obtained by applying to 
the human ventricular IKr model the same alterations as in [22]. Protocols are described 
in [22]. Bottom table of Figure 1D summarizes the modifications introduced in the IKr 
model to simulate the effects of the N588E and N588K mutations. The mutated residue 
is remote from the drug-binding pocket in the channel pore [22], and experiments 
suggest values of drug affinities for the mutated IKr channels are unchanged from WT 
 8 
[22]. We also made this assumption in the model. The top and bottom panels of Figure 
1F include experimental data and simulation of the Hill plots of dofetilide binding for 
WT, N588E and N588K, respectively. The differential blocks in N588E and N588K 
mutated IKr produced by dofetilide predicted by our model simulations are in close 
agreement with the experiments performed in Chinese hamster ovary (CHO) cells [22].   
(Approximate position of Figure 1) 
 
As shown in Figure 2A, the Markov model representation of IKr from Fink et al. 
includes three closed states (C3, C2 and C1), a conducting open state (O) and an 
inactivation state (I). This channel model was incorporated into the O’Hara et al. human 
ventricular action potential (AP) model [14] (black traces in top row of Figure 3) and its 
maximum conductance was scaled to elicit the same peak IKr value as the original 
O’Hara model at 1Hz (black traces in middle row of Figure 3).  
(Approximate position of Figure 2) 
 
We carried out “in silico mutagenesis” by modifying discrete transition rates (orange 
arrows in model schematic Figure 3) in the computational model that led to targeted 
modification of channel activation, inactivation, deactivation or recovery from 
inactivation (from left to right) as indicated and resulting prolongation of the APD90 by 
50 ms, 20 ms and 10 ms. These changes were intended as prototypical latent, mild and  
moderate (red) allelic variants in hERG that may underlie a predisposition to aLQTS. 
The effects of moderate variants led to a 50 ms APD90 prolongation (top row), IKr 
reduction (middle row) and open state probability (bottom row). Deactivation mutants 
(second column) result in the smallest IKr among the simulated functional mutants and 
with the most altered morphology (red arrow in middle row). Deactivation mutants are 
most severe because IKr current arises at the critical late juncture in the action potential 
to cause final AP repolarization precisely because of the imbalance between rapid 
recovery from channel inactivation and subsequent slow deactivation. This imbalance 
normally results in channels residing in the open state during repolarization. Mutations 
that increase the rate of deactivation are dire: they lead to a marked reduction in channel 
open probability (red arrow in bottom row) by promoting channel closure.  
(Approximate position of Figure 3) 
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Figures 2B-F shows the IKr Markov model described above with multiple distinct drug 
bound configurations (lower row of states in each panel indicated by subscript “d”) in 
panels B though F. Because ion channel targeting drugs display complex properties 
determined by preferential binding to distinct conformation states and/or distinct 
affinity to discrete states, we simulated a wide variety of likely combinations of drug-
channel interactions (Figures 2B-F): drugs that exclusively bound in the closed (Figure 
2B), open (Figure 2C) or inactivated (Figure 2D) states, as well as drugs binding 
simultaneously to both the closed and open states, (Figure 2E), or to both the open and 
in the inactivated state, (Figure 2F) were analyzed in detail by testing a range of 
association and dissociation rates for the various drug configurations. The initial 
estimated association and dissociation rates were assumed similar to the association rate 
of dofetilide and an intermediate value of the dissociation rates of dofetilide. The values 
0.511 µM-1s-1 and 0.003606 s-1 were used as the baseline association and dissociation 
rates. Rates were then varied in the test simulations by increasing them 10-, 50-, 100-
fold or reducing rates 10- or 100-fold. 
 
3.1 Latent Defective Activation  
In first column of Figure 4, the effects of latent (blue), mild (green) and moderate (red) 
variants of activation (orange arrow in Markov diagram indicates the altered transition 
rate) led to varying degrees of APD90 prolongation (10, 20 and 50 ms, respectively), 
consistent with the degree of change to the activation rate (first row). We next carried 
out multiple simulations with 21 IKr blocking drugs spanning a variety of inherent 
kinetic properties, conformational state specificities and concentrations. The model 
predicts that most drugs were unable to differentiate between normal and mutant 
channels. Low doses of drugs that exclusively bound to a single IKr state, drugs that 
simultaneously bound to open and inactivated channels, and drugs that bound with low 
affinity to closed but high affinity to the open state produced similar APD90 
prolongation in normal and mutant channels. 
 
However, the model predicted that drugs binding to closed and open states with lower 
affinity to the open state (Actilide_Oc) amplified mutant effects on APD90 prolongation 
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in activation mutants compared to WT (the pink arrow in the Markov scheme indicate a 
lower affinity of the drug in that state). A drug (depicted in the Markovian scheme at the 
top of the first column) with these properties was identified in the simulations to best 
unmask the mutant phenotype. Exposure to 3 nM (low dose) Actilide_Oc_1 
(supplemental material, Table S3) (Figure 4, middle row of the first column) increased 
the APD90 difference between WT and impaired activation cells from 10 ms to 16 ms, 
from 20 ms to 33 ms and from 50 ms to 83 ms. Differences in APD90 between WT and 
impaired activation cells were also sensitive to Actilide_Oc_1 concentration. Indeed, 
addition of 12 nM (high dose) Actilide_Oc_1 (Figure 4, bottom row of the first column) 
increased the APD90 differences between WT and cells with defective activation from 
10 ms to 20 ms, from 20 ms to 43 ms and from 50 to 118 ms, respectively. Addition of 
other drugs binding in the closed and open state with lower affinity to the open state 
(Actilide_Oc_2, Actilide_Oc_3 and Actilide_Oc_4) but with different dissociation rates 
(supplemental material, Table S3) produced similar APD90 differences between WT and 
cells with defective activation as Actilide_Oc_1 in the steady state. However, the 
duration of the transitory period from drug application to the steady state depended on 
the specific association and dissociation rates values of the drug and faster rates led to 
shorter transitory periods.  
 (Approximate position of Figure 4) 
 
3.2 Latent Defective Deactivation  
In second column of Figure 4, the effects of latent, mild and moderate variants of 
deactivation (orange arrows in Markov diagram indicate the altered transition rate) led 
to corresponding varying degrees of APD90 prolongation (first row of the second 
column). We next simulated the effect of a wide variety of IKr blocking drugs on these 
deactivation mutants. Surprisingly, the model predicts that most drugs preferentially 
prolonged the steady state APD90 in mutated cells with marked faster deactivation. This 
result indicates that allelic variants affecting deactivation would lead to increased 
sensitivity to a wider range of IKr blockers, and consequently, an increased likelihood of 
aLQTS. This is in accordance with the fact that deactivation mutants (Figure 3, second 
column) result in the smallest IKr among the simulated functional mutants and with the 
most altered morphology (Figure 3, red arrow in middle row).  
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Drugs binding in the closed and open state with significantly lower affinity in the open 
state produced the largest APD90 differences between WT and mutated cells with faster 
deactivation, as in the case of activation mutants, but substantially longer APD90 
prolongations were observed in deactivation mutants. The second column of Figure 4 
shows the simulation results of exposure of deactivation mutations to one drug of this 
type, Actilide_Co_1. In this case, application of 3 nM (low dose) Actilide_Co_1 (Figure 
4, middle row of the second column) amplified the APD90 difference between WT and 
deactivation mutant cells from 10 ms to 113 ms (blue), from 20 ms to 181 ms (green) 
and from 50 to 294 ms (red). Addition of 12 nM (high dose) of this drug (Figure 4, 
bottom row of the second column) enhanced the APD90 difference between WT and 
deactivation mutant cells from 10 ms to 177 ms (blue) and generated patterns of early-
afterdepolarizations (EADs) in deactivation mutants whose APD90 is 20 ms and 50 ms 
longer than WT under drug-free conditions (green and red, respectively).  
 
Differential APD90 prolongation was also induced by drugs binding in the open and 
inactivated state with a much lower affinity in the open state. Indeed, addition of 3.6 nM 
(low dose) Inactilide_Oi_1 increased the APD90 differences between WT and cells with 
defective deactivation from 10 ms to 102 ms, from 20 ms to 167 ms and from 50 to 262 
ms (not shown). Exposure to 10.55 nM (high dose) of this drug also further increased 
the APD90 differences between WT and deactivation mutants from 10 ms to 164 ms and 
generated EADs in AP in deactivation mutants whose APD90 is 20 ms and 50 ms longer 
than WT under drug-free conditions (not shown). Drugs exclusively binding in one IKr 
state still unmasked this type of defect in moderate mutants, but they produced smaller 
APD prolongations in deactivation mutants than the previous drugs. For example, 
Drug_C1 (supplemental material, Table S3) produced a 96 ms APD90 difference 
between WT and the deactivation mutation cell that is 50 ms longer than WT in drug-
free conditions. Finally, drugs binding in the closed and open state with a much lower 
affinity in the closed state and drugs binding in the open and inactivated state with a 
much lower affinity in the inactivated state did not help to discern between WT and 
mutants, as 67 ms and 64 ms steady state APD90 differences between WT and the 50 ms 
APD90 prolongation mutation under drug-free conditions were observed during low 
doses drug exposure, respectively. Again, drug-induced steady-state APD prolongation 
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depended on the states where the drug bound and the preferential binding to a channel 
state, regardless of the diffusion rate of the drug. 
 
The previously explained amplification of the effects of defective IKr deactivation on 
APD90 prolongation produced by most drugs is directly related to the extent of the 
reduction in current. Indeed, Actilide_Oc, which is the type of drug that most amplifies 
defective IKr deactivation indicated by APD90 prolongation, is the one that most reduces 
the fast deactivated IKr current, closely followed by Inactilide_Oi (see supplemental 
material, Figure S2). 
 
3.3 Latent Defective Inactivation  
The first row of the third column of Figure 4 shows the time course of the APs elicited 
by WT and cells harboring three modeled inactivation mutations yielding 10 ms, 20 ms 
and 50 ms APD90 prolongation relative to WT (orange arrows in Markov diagram 
indicate the altered transition rate). Our simulations predicted that low dose of simulated 
drugs that bound exclusively to one discrete IKr state and drugs binding both the closed 
and open state with low affinity to the open state were not able to amplify differences 
between WT and inactivation mutants and were thus unable to unmask the mutations. 
Indeed, exposure to 10 nM (low dose) of Drug_C1 (supplemental material, Table S3) 
only increased in 3 ms the APD90 difference between WT and the inactivation mutant 
whose APD90 was 50 ms longer than WT in drug-free conditions and Actilide_Oc_1 
(supplemental material, Table S3) did not amplify it.  
 
Drugs interacting with low affinity to closed and high affinity to the open states 
performed somewhat better, as 750 nM (low dose) of Actilide_Co (supplemental 
material, Table S3) only increased in 7 ms the APD90 difference between WT and the 
inactivation mutant whose APD90 was 50 ms longer than WT in drug-free conditions.  
 
However, a drug with low affinity open state block (pink arrow in model schematic) and 
higher affinity inactivated state (black arrow) very effectively unmasked IKr mutants 
causing impaired inactivation. Specifically, application of 3.6 nM (low dose) and 10.55 
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nM (high dose) Inactilide_Oi_1 (supplemental material, Table S3) (Figure 4, middle 
and bottom row of the third column, respectively) enhanced the APD90 differences 
between WT and defective inactivation cells from 10 ms to 15 ms and 19 ms (blue), 
from 20 ms to 28 ms and 39 ms (green) and from 50 to 76 ms and 113 ms (red), 
respectively. In this case, the steady state APD prolongation observed during drug 
exposure also depended most on the states where the drug bound and the preferential 
binding state regardless of its diffusion rate. 
 
3.4 Latent Defective Recovery from Inactivation  
Low doses of each drug were applied to WT and cells containing a simulated 
mutagenesis affecting the rate constant controlling IKr recovery from inactivation (RFI, 
rate from I to O) indicated by the orange arrow in the schematic. Simulated mutations 
yielded 10 ms, 20 ms and 50 ms APD90 prolongation compared to WT (Figure 4, first 
row of the fourth column). As expected, this simulated defect primarily affected the 
fractions of channels in the inactivated and open state, much like mutations that affected 
the inactivation transition. A drug with low affinity block in the open state (pink arrow) 
and preferential higher affinity block in the inactivated open state (black arrow) as 
depicted in the Markovian scheme at the top of the fourth column of Figure 4, amplified 
the mutation effect, observed by more APD90 prolongation in mutated cells with 
impaired recovery from inactivation than in WT cells. In this case, application of 3.6 
nM (low dose) and 10.55 nM (high dose) Inactilide_Oi_1 (Figure 4, middle and bottom 
rows of the fourth column, respectively) augmented the APD90 difference between WT 
and RFI mutant cells from 10 ms to 15 ms and 18 ms (blue), from 20 ms to 27 ms and 
37 ms (green) and from 50 to 76 ms and 99 ms (red), respectively.   
 
3.5 M54T hMiRP1 Mutation   
We also applied this procedure to the naturally occurring hERG mutation, the M54T 
MiRP1 mutation, which has been implicated in drug-induced LQTS and arrhythmia [1, 
4]. Figure 5 compares the experimental (top row) and the simulated (bottom row) steady 
state activation curve (left column) and the deactivation time constant curve (right 
column) for WT (squares) and M54T hMiRP1 mutated channels (triangles). Protocols 
are described in Abbott et al. [4]. This mutation is known to moderately increase the 
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voltage dependence of activation by reducing the activation slope without altering the 
half activation potential [4]. The experimentally measured activation slope was 9.5 mV 
and 7.5 mV for WT and M54T hMiRP1 mutated channels, respectively [4]. Therefore, 
the activation slope of these mutated channels is 75.8 % the slope of the WT channels. 
The activation slope of the simulated M54T hMiRP1 mutated channels is 75.5 % the 
slope of the simulated WT channels. Importantly, M54T hMiRP1 mutated channels are 
also known to deactivate approximately twice as fast as WT [4]. Our simulated M54T 
hMiRP1 mutated channels reproduce this alteration (right panels). In addition, 
experimental results evidence that M54T hMiRP1 mutated channels were like wild type 
in their steady state inactivation [4]. The simulated M54T hMiRP1 mutation did not 
alter the steady state inactivation curve in our model (not shown). Moreover, additional 
experiments reported reduction of 39 % in current density at - 40 mV in M54T hMiRP1 
mutated channels [1]. The alteration of the transition rates in our simulated M54T 
hMiRP1 mutated channels caused a similar reduction in current density (not shown), 
therefore the maximum conductance of the mutated channels was not modified. Rate 
constants for the simulated M54T hMiRP1 channels are provided in the supplemental 
material (Table S2). Quantitative differences between the experimental results of the 
M54T MiRP1 latent mutation and the simulations (Figure 5) derive from the differences 
in the cells and subunits of the channels used in the characterization of the mutation and 
the data used to model the IKr used in our study. Indeed, the experimental data (shown in 
the top row of Figure 5) was obtained from hMiRP1/HERG channels expressed in 
Xenopus laevis oocytes [4] and the IKr model proposed by Fink et al. [13] and used in 
our simulations for WT cells was fitted to experimental data from hERG in HEK cells 
and human myocytes and incorporated relative changes resulting from the mutation into 
the baseline Fink model.   
(Approximate position of Figure 5) 
 
We incorporated the M54T hMiRP1 channels into the AP model. The M54T hMiRP1 
mutated (orange) APD90 was 11.6 ms longer than WT (black) APD90 in isolated 
endocardial cells (Figure 6A). As we did with the virtual mutations, we also observed 
the amplification of the APD90 differences between M54T hMiRP1 mutated and WT 
cells under drug exposure. The virtual drug types that most amplified the APD90 of 
M54T hMiRP1 mutants were Actilide_Co and Inactilide_Oi. Specifically, low doses of 
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both Actilide_cO_2 and Inactilide_Oi_2 led to a 46 ms difference between M54T 
hMiRP1 mutants and WT cells. Addition of other types of drugs did not help to 
differentiate between M54T hMiRP1 mutants and WT cells. For example, exposure to 
low dose of Drug_C_2 only produced 3 ms additional difference in APD90 between 
M54T and WT cells compared to drug-free conditions. These results resembled those 
obtained with the prototypical latent fast deactivation mutant. It supports the validity of 
our method to predict the drug types that affect a particular mutation, as fast 
deactivation is the main IKr alteration produced by M54T hMiRP1 mutation [4]. We also 
simulated the effects of the real drug dofetilide in the presence of this naturally 
occurring mutation. Exposure to 16 nM (low dose) and 48 nM (high dose) dofetilide 
increased the APD90 difference between WT (black) and mutants (orange)  from 11.5 
ms (Figure 6B) to 46 ms (Figure 6C) and  65 ms (Figure 6D), respectively. It is notable 
that dofetilide and Inactilide_Oi_2 produced similar results. Dofetilide could be 
classified as an Inactilide_Oi drug because it binds in the open and in the inactivated 
states [25] with a 70-fold preferential binding to the inactivated state relative to the open 
state [22]. 
 
As the ECG is the electrical signal used for clinical diagnosis rather than the APD in 
isolated cells, we also simulated the pseudo-ECG using a 1-dimensional model of the 
transmural wedge to investigate the potential use of this dofetilide modification to 
unmask silent mutation carriers. Our results (Figure 6, bottom row) show that the M54T 
hMiRP1 mutation produced a 6 ms prolongation of the simulated QT interval duration 
(WT QT interval duration = 392 ms, Figure 6D) under drug-free conditions. The 
presence of 16 nM (low dose) and 48 nM (high dose) of dofetilide amplified the QT 
interval duration difference between WT and mutant to 47 ms (Figure 6E) and 105 ms 
(Figure 6F), respectively. The generation of EADs in midmyocardial cells (see inset of 
Figure 6F) in the transmural strand after the application of high dose modified dofetilide 
led to more aggravated differences in the QT interval between WT and M54T mutated 
cells than in the APD90 registered in isolated cells. The development of the EAD in the 
M cell only leads to an apparent increase in dispersion of repolarization, observed on 
the simulated ECG as a broadening of the t-wave (due to very long repolarization in the 
M-cell) and also an increase in the amplitude of the t-wave (resulting from the large 
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voltage dispersion (gradient)) that occurs when the epicardial cell has repolarized and 
the M-cell is depolarized due to the EAD.  
 
Simulated pseudo-ECGs at 1 Hz for WT in the presence of high doses of every drug 
considered in this study are shown in Figure S5 in the supplemental material. Although 
they are very similar, small differences in the T-wave are observed. Indeed, the drugs 
that most increase the amplitude of the T-wave are Inactilide_Oi, Inactilide_Io and 
Actilide_Co, followed by drugs binding and unbinding in one state of the channel 
(Drug_C, Drug_O and Drug_I). Actilide_Oc caused minimal increase in the amplitude 
of the T-wave (see Figure S6 in the supplemental material).  
(Approximate position of Figure 6) 
We also simulated the addition of potassium channel activators to mitigate the effects of 
dofetilide exposure on M54T hMiRP mutated channels to dramatically prolong APD90. 
As M54T hMiRP mutated channels exhibit fast deactivation, our analysis suggests that 
a channel opener that slows deactivation would be  the postulated as the ideal channel 
opener. Therefore, type 1 agonists, which slow deactivation and attenuate inactivation, 
would be more appropriate in this case than type 2 agonists, which attenuate 
inactivation without slowing deactivation [28]. Figure 7A shows that addition of 230 
nM RPR260243 (orange thick line), a type 1 agonist, following application of 16 nM 
dofetilide in M54T hMiRP1 mutated cells at 1 Hz (orange thin line) shortened APD90 to 
the level observed in WT cells in the presence of 16 nM dofetilide at 1 Hz (black thin 
line). In other words, adjunctive therapy with a type 1 hERG channel activator 
cancelled the effects of the M54T mutation.  This also was observed at 0.67 Hz and 2 
Hz (2.3 ms and 7.8 ms APD90 difference, respectively). Importantly, the reduction in 
APD90 predicted by the model simulations in both WT and M54T hMiRP mutated cells 
in the presence of 230 nM RPR260243 was comparable (~26 ms, see Figure 7B at 1Hz) 
and the shortening was dose-dependent (see Figures 7B and 7C at 1Hz).  This prediction 
suggests that the type 1 hERG channel activator did not discriminate between WT and 
mutant channels, suggesting that the drug would not cause unexpected effects through 
interaction with the mutation.  
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Next, we used our in silico method to predict properties to improve the performance of 
this activator. Our simulations suggest that elimination of the effects of RPR260243 on 
inactivation (RPR260243_mod) would minimize the shortening of the APD90 in the 
absence of IKr blockers while reducing the APD90 prolongation of M54T hMiRP1 
mutated cells and the related in silico mutant in the presence of dofetilide. Indeed, 
addition of 1.2 mM RPR260243_mod to 16 nM dofetilide in M54T hMiRP1 mutated 
cells normalized APD90 to WT in the presence of 16 nM dofetilide at 1Hz (Figure 7D), 
0.67 Hz and 2 Hz (0.7 ms, 1.5 ms and 18.4 ms APD90 difference, respectively). 
Importantly, this concentration of RPR260243_mod did not reduce the APD90 of WT 
and M54T hMiRP1 mutated cells in the absence of dofetilide (Figure 7E), except for a 
small 4 ms reduction at 2 Hz. In addition, a ten-fold increase in RPR260243_mod 
concentration did not reduce the APD90 of WT cells in the absence of dofetilide at 1 Hz  
(Figure 7F) and only reduced it in 6 ms at 2 Hz. Similar results were obtained when 
these channel openers were added to in silico mutated cells with hastened deactivation.  
(Approximate position of Figure 7) 
 
3.6 Effects of heart rate and combination of mutations   
To further investigate the genetic predisposition to aLQTS, the influence of heart rate 
and the presence of silent mutations on other ionic currents were also analyzed. 
 
3.6.1 Heart rate  
We next tested the rate dependence of pharmacological amplification of IKr allelic 
variants on APD90 during exposure to the drugs that most amplified them at 1 Hz 
(Actilide_Oc, Inactilide_Oi and drugs exclusively binding and unbinding in the closed, 
open or inactivated states).  Drugs were tested at fast (2 Hz) and slow frequencies (0.67 
Hz). Figure 8 shows the rate dependence of the effects of activation (A), deactivation 
(B), inactivation (C) and recovery from inactivation (D) Ikr mutants producing a 50 ms 
prolongation of APD90 under drug-free conditions at 1Hz on AP90 under drug-free 
conditions (black) and under exposure to low dose Actilide_Oc_1 (red), 
Inactilide_Oi_1(green), and Drug_C1 (blue). Our simulations show that the same drugs 
that amplified mutant effects on APD90 prolongation at 1 Hz also amplified them at fast 
and slow frequencies, although the magnitude of the APD90 prolongation depended on 
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the type of the drug, the mutant and the heart rate. In general, the slower the frequency, 
the larger the mutant amplification on APD90 predicted. As observed at 1 Hz, APD90 of 
deactivation mutants were preferentially prolonged by most drugs, especially by 
Actilide_Oc and Inactilide_Oi. Low doses of these drugs produced EADs at 0.67 Hz 
and APD90 longer than 500 ms at 2 Hz (Figure 8B). Drugs binding in only one state also 
enhanced the APD differences between deactivation mutants and WT, although to a 
lesser extent (Figure 8B). In addition, the effects of impaired activation on APD90 were 
especially amplified under exposure to Actilide_Oc, regardless of the pacing rate 
(Figure 8A). Finally, Inactilide_Io was the type of drug that most amplified inactivation 
and recovery from inactivation mutant effects on APD90 prolongation at all frequencies 
(Figures 8C and 8D). 
(Approximate position of Figure 8) 
 
Differences between WT cells and IKr mutants on APD heart rate adaptation to abrupt 
changes in pacing frequency under drug-free conditions and under exposure to selected 
IKr-drug interactions were also investigated (see supplemental material, Figure S3 and 
Table S4). WT cells exhibited a biphasic APD accommodation to abrupt changes in 
pacing rates under drug-free conditions as observed experimentally. Notably, the 
simulated time constants (shown in Figure S3 and Table S4) were close to the values 
experimentally recorded [17, 20] and simulated in other works [19, 20]. The biggest 
differences between WT cells and IKr mutants on APD adaptation to abrupt changes in 
pacing rate under drug exposure were found in slow_decelarating and slow_accelarating under 
Inactilide_Oi_1 exposure, especially between WT cells and activation IKr mutants (see 
supplemental material, Figure S3 and Table S4). 
 
3.6.2 Combination with other silent mutations  
APD90 of control cells and IKr mutants under drug free conditions were prolonged in the 
presence of IKs or INaL silent mutations, although the extent of APD90 prolongation 
depended on the specific combination of mutations. Indeed, APD90 of activation, 
deactivation, inactivation and recovery from inactivation IKr mutants whose APD90 was 
50 ms longer than WT under drug-free conditions exhibited a 18 ms, 24 ms, 29 ms and 
29 ms prolongation in the presence of IKs silent mutations and a 18 ms, 25 ms, 25 ms 
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and 25 ms prolongation in the presence of INaL mutations, respectively (see 
supplemental material, Figure S4). 
 
Amplification of the effects of IKr mutants on APD90 under drug exposure was further 
enhanced when IKr mutants were combined with IKs or INaL mutations, although INaL 
silent mutations exerted a smaller influence (Figure S4 and Table S5). Importantly, 
deactivation defective mutants in combination with IKr and INaL silent mutations 
routinely developed EADs under exposure to low doses of Actilide_Oc and 
Inactilide_Oi (Figure S4). It is to be noted that Inactilide_Oi amplified the effects of 
impaired inactivation and recovery from inactivation IKr in APD90 prolongation much 
more effectively in combination with latent IKs mutants (Figure S4). Indeed, 3.6 nM 
(low dose) of Inactilide_Oi_1 prolonged the effects of IKr inactivation and recovery 
from inactivation mutants on APD90 prolongation from 50 ms to 73 ms in the absence of 
IKs latent mutants (Figure 4) and from 49 ms to 96 ms in the presence of IKs latent 
mutants (Figure S4). The bigger influence of IKs silent mutants on the effects of 
defective IKr on APD90 than INaL silent mutants may be related to the fact that both IKr 
and IKs contribute to the repolarization reserve of the cells, so a reduction of both 
currents can create a synergistic effect on APD90 prolongation. 
 
4. Discussion 
4.1 Main findings 
We used a computational approach to identify characteristics of drugs that selectively 
unmask latent, mild and moderate IKr mutations. The simulations predicted that drugs 
exhibiting high affinity closed-state and low affinity open-state block (Actilide_Oc) or 
high affinity inactivated-state and low affinity open-state block (Inactilide_Oi) unmask 
aLQTS arising from IKr gene variants. Exposure to such drugs caused dramatic APD 
prolongation in the setting of mutations causing faster IKr deactivation. By contrast, cells 
with impaired activation were predicted to develop the longest APDs following 
exposure to drugs exhibiting high affinity closed-state binding and low affinity open 
state block (Actilide_Oc). Addition of drugs with other properties to cells with impaired 
activation produced less APD prolongation. Defects in channel inactivation and 
 20 
recovery from inactivation were revealed with drugs exhibiting high affinity 
inactivated-state binding and low affinity open-state block (Inactilide_Oi) while they 
were hidden under exposure to other type of drugs. Importantly, our method could be 
expanded and used to predict which type of drug would most affect any characterized 
IKr mutation.  We have constructed a comprehensive library of mutant and drug 
interaction templates that can be readily modified to predict interactions of interest.   
 
To our knowledge, this is the first time that a provocative test has been shown to 
selectively differentiate mutations in an ionic channel. This study, which is supported 
by experimental evidence, intends to be a proof of concept for future provocative tests 
in IKr and for the design of provocative tests in other ionic currents.  
 
Our results suggest the specific properties of IKr blocking drugs most likely to cause 
aLQTs and amplify the impact of allelic variants in IKr genes in those at risk of 
development of drug-induced arrhythmias. This study reinforces a widely understood 
concept – that not all IKr block is the same. But, our results also suggest specific 
properties of IKr block that should be included in pre-clinical screening to ensure 
cardiac safety of all commercial therapeutics. Our study strongly suggests that an 
observation of reduction of current comprises insufficient information to evaluate 
cardiac safety: Screening must include kinetic measurements of hERG block.  
 
4.2 Latent mutations  
Despite the work done on the identification of proarrhythmic risk factors, prediction of 
the development of arrhythmic episodes in an individual subject remains unattainable 
[29]. It is well-known that genetic factors may increase the proarrhythmic risk, 
however, the importance of altered gene expression in drug-induced TdP development 
is not clear [29]. Our work intends to begin to shed light on these questions and it could 
be used to predict the characteristics of the drugs that are more proarrhythmic in the 
presence of any characterized IKr mutation. In our simulations the longest drug-induced 
APD prolongations were observed in deactivation mutated cells (Figure 3, second 
column) and most prototypical drugs preferentially prolonged APD in deactivation 
mutants than in WT cells, especially Actilide_cO and Inactilide_Oi, dofetilide being 
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notably similar to the latter. Clinical and experimental observations relating accelerated 
deactivation to aLQTS support our results. One patient with normal QT interval that 
suffered procainamide-induced arrhythmia had the M54T-hMiRP1 mutation that 
accelerates deactivation [1], which has been also observed in one patient among 230 
patients with sporadic LQTS but not in 1010 controls [4]. Our study suggests that this 
latent mutation is prone to develop aLQTS especially under provocation with dofetilide-
like drugs and Actilide_cO. In addition, the S706F/KCNH2 and M756V/KCNH2 
mutations have been associated to aLQTS [30]. These mutations accelerate channel 
deactivation and inactivation and alter the steady state inactivation curve [30]. Our 
study suggests that these alterations on IKr kinetics could lead to aLQTS especially in 
the presence of Inactilide_Oi (like dofetilide), as observed in the virtual inactivation, 
recovery from inactivation and deactivation mutants, and Actilide_cO, similar to the 
prototypical deactivation mutants. In addition, the A561P HERG mutation, which 
significantly accelerates the deactivation and shifts the steady state activation curve, has 
been linked to LQTS and clobutinol-induced arrhythmic episodes [31]. The alterations 
in deactivation and activation kinetics produced by this mutation also suggest a 
preferential prolongation of the APD in the presence of Actilide_cO and Inactilide_Oi. 
 
Other IKr kinetic defects have also been implicated in aLQTS and arrhythmias, 
consistent with our predictions of APD prolongation resulting from altered activation, 
inactivation and recovery from inactivation in the presence of certain drugs (Figure 4, 
first, third and fourth column). In principle, our work suggests that these mutations 
would be less proarrhythmic than deactivation mutants, although it also depends on the 
severity of the IKr alterations. The D342V/KCNH2 and H492Y/KCNH2 mutations 
mostly alter inactivation kinetics and have been associated with aLQTS [30]. According 
to our study, only analogs of drugs like Inactilide_Oi and dofetilide, would amplify the 
effects of these mutants. As previously mentioned, the S706F/KCNH2 and 
M756V//KCNH2 in addition to accelerate deactivation they also accelerate inactivation 
[30]. Moreover, the polymorphism R104L in hERG causes defects in activation and 
inactivation and has been related to the incidence of TdP induced by dofetilide [32]. 
Indeed, our study suggests that Inactilide_Oi, like dofetilide, and Actilide_cO could 
significantly prolong the APD in this mutation due to its defective inactivation and 
activation, respectively. 
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4.3 Provocative tests 
Potent sodium blockers, like flecainide, have been used to unmask Brugada Syndrome 
in patients with concealed forms of the disease [9]. More recently, combined sodium 
and calcium block has been shown to be more effective for revealing this disease [10]. 
In addition, epinephrine and isoproterenol, which enhance beta-adrenegic stimulation, 
unmasked some silent LQT1 mutation carriers [8, 33]. Sotalol, a potent IKr blocker, has 
been shown to uncover altered repolarization [11], while another, erythromycycin, 
prolonged the T peak-to-end interval in LQT2 mutations, causing only modest QT 
prolongation in LQT1 and LQT2 mutations with normal QT interval [12]. In the 
aforementioned works drugs were used to reveal the genetic defects by reducing the 
repolarization reserve. However, in our study IKr-drug interactions are designed to 
reveal the specific impaired IKr kinetics. Our results indicate that unmasking of specific 
impaired IKr kinetics would be possible using drugs with disparate affinities in the 
binding states of the IKr channel. Our results suggest that dofetilide could be used to 
unmask defects in channel deactivation, inactivation and recovery from inactivation as it 
exhibits high affinity inactivated-state binding and low affinity open-state block 
(Inactilide_Oi). 
 
When a drug exhibits variable state affinity, the extent of IKr reduction depends on the 
affinity of the drug in each state and the probability of residency of the channel in 
conformations where the drug interacts. Therefore, a mutation increasing the probability 
of the state where the drug is more potent will favor the block of the channel while a 
genetic defect decreasing that probability would minimize the block. Importantly, this 
mechanism could also permit the selective unmasking of silent mutations of other ionic 
currents, such as INa or IKs, which would improve diagnostic of all types of LQTS and, 
subsequently, the therapy of the LQTS.  
 
Major advances in the pharmacological field have occurred including the automated 
patch-clamp, which allows high-throughput compound screening [34]. In addition, 
molecular modeling techniques have been implemented for the assessment of the 
blocking ability of drugs to the hERG1 pore domain [35]. Moreover, crystal structures 
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of different conformational states of a K+ channel in bacteria have been identified [36], 
which would allow the estimation of the differences of drug affinity in the different 
states of the channel. These and other new advances could be used in combination with 
our computational approach for drug and disease screening and identification and 
production of drugs or small molecules for provocative tests. 
 
4.4 Drug safety 
Our results indicate that drugs with disparate affinities to conformational states are 
more likely to amplify APD differences between WT and mutated cells than drugs with 
similar affinities to all states. Examples of drugs with disparate affinities to 
conformational states and related to drug-induced QT prolongation and arrhythmia are 
dofetilide (which exhibits a 70-fold preferential binding to the inactivated state relative 
to the open state), astemizole, cisapride, dl-sotalol, and terfenadine [22]. Our results also 
suggest that exactly these kinds of drugs should be avoided in pharmacological 
therapies or accompanied by IKr openers, as they could favor the appearance of aLQTS 
and arrhythmias in patients with common allelic variants in genes encoding the proteins 
constituting IKr. Therefore, the relative potency of block in the states that the drug 
interacts with the channels should be measured in the process of pre-clinical drug 
screening. Indeed, our simulations suggest that if these potencies were realized in the 
preclinical screen, then appropriate adjunctive therapy with a hERG channel activator 
could be employed to cancel any additive effects of a mutation. 
 
Our results confirm that the risk of TdP is not solely determined by degree of blockade 
of IKr [3, 29]. Pharmacokinetic–pharmacodynamic relationships are known to be 
relevant for the development of TdP [29]. In this study, we show that the kinetics of 
block is crucial for amplifying the kinetic defects of the channel that prolong the APD, 
which may favor the generation of arrhythmias. 
 
4.5 Limitations  
In this work we used the same values of drug affinities for WT and mutated IKr cells. 
Severe mutations themselves can, however, modify the affinity of the drug [27] by 
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indirect allosteric modifications in the structure of the channel protein [27]. The subtle 
mutations, as simulated here, would not be expected to significantly modify the 
structure of the channel. It is also worth mentioning that some IKr blocking drugs have 
been shown to modify channel trafficking [37]. In this paper, this effect has not been 
specifically taken into account, but would be interesting to consider with sufficient data 
to inform the model in future studies [37].  
In this study a wide variety of virtual drugs has been simulated in order to predict the 
most potentially lethal combinations of drug properties and IKr kinetic abnormalities. 
Our results show that amplification of IKr kinetic defects on APD is observed under 
exposure to drugs with disparate affinities to conformational states of the IKr channel 
because of the differences in the residence of the channels in the binding states between 
the mutated and WT channels. Our study could be extended by considering an almost 
infinite possibility of additional virtual drugs, for example drugs with varying affinities 
to discrete closed states. Tools utilized in this study for simulating the effects of drugs 
and mutations on AP will be available upon request.  
Finally, our in silico simulation approach allows investigations that would be difficult 
to undertake in vitro, such as precise kinetic drug properties and mutations, and the use 
of human cells. Our model of IKr drug interaction has been experimentally validated as 
it successfully reproduced drug sensitivities of two hERG mutations, N588E and 
N588K, to IKr dofetilide block.  Although it is outside of the scope if this paper, the 
performance of experiments to compare drug block for WT and KCNE2 mutants at 
different dofetilide concentrations would be also interesting. These experiments could 
also be used to validate Markov simulations of channel block. 
 
Appendix A. Supplementary data 
Supplementary data related to this article can be found in the online version. 
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Figure legends 
Figure 1. Dofetilide IKr block in WT and IKr mutant cells. Onset of WT IKr block by 50 
nM dofetilide (A, B) and 3 M dofetilide washout (C), conductance voltage curves (E) 
and Hill plots (F) of dofetilide-binding to WT, N588E-hERG and N588K-hERG  
mutants. In panels A-C, symbols correspond to experimental results [24] (A), [25] (B) 
and [26] (C) and solid lines represent the model predictions. Top panels and bottom 
panels in E and F represent the experimental [22] and the predicted results, respectively. 
Panel D summarizes the association (k, µM-1s-1) and dissociation (r, 10-3s-1) rates for 
dofetilide-IKr interaction, the values of clinical [23] and simulated QT intervals at 60 
bpm under drug-free and under a therapeutic dofetilide dose and the alterations 
introduced in the IKr model to simulate the effects of the N588E and N588K mutations. 
In each case, ionic concentrations and temperature (37 ºC, 28 ºC and 22 ºC for Panels A, 
B and C, E and F, respectively) were fixed to mimic the experimental conditions.  
Experimental data from [22] is reproduced with permission. Experimental data from 
[24] (http://onlinelibrary.wiley.com/doi/10.1113/jphysiol.2001.013296/full, DOI: 
10.1113/jphysiol.2001.013296) is reproduced with permission. Experimental data from 
[25] is reproduced with kind permission from Springer Science and Business Media. 
The onset of block by 0.5 μM dofetilide with repetitive pulsing is voltage-
dependent.Two-second depolarizing pulses to –40, 0 or +60 mV were applied with a 12-
s interpulse interval (IPI). Pulses to –40 mV were applied for a longer period to allow 
for steady-state inhibition. All values are mean ±SEM (n=4, 3 and 4 for –40, 0 and +60 
mV respectively). Experimental data from [26] is reproduced by permission of Oxford 
University Press.  
 
Figure 2. Fink et al. Markov model of the human IKr channels [13] (A) and simulated 
drug-IKr interaction models (B, C, D, E, F) with nondrug bound and drug bound estates 
(d), kC, kO and kI are the association rates constants in the closed, open and inactivated 
states, respectively, D is the drug concentration and rC, rO and rI are the dissociation rate 
constants in the closed, open and inactivated states, respectively. Binding states are red 
colored.  
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Figure 3. Simulated steady state AP (top row), IKr (middle row) and open state 
probability (bottom row) for endocardial WT (black) and mutated cells with altered IKr 
activation (first column), deactivation (second column), inactivation (third column) and 
recovery from inactivation (forth column) producing a 50 ms (red) APD90 prolongation 
under drug-free conditions. Markovian schemes of the simulated IKr mutants are 
depicted at the top. The orange arrows represent the transition rate that has been altered 
to simulate each mutation. 
Figure 4. Simulated steady state AP for endocardial WT (black) and mutated cells with 
altered IKr activation (first column), inactivation (second column), deactivation (third 
column) or recovery from inactivation (fourth column) producing a 10 ms (blue), 20 ms 
(green) and 50 ms (red) APD90 prolongation under drug-free conditions (top row) and in 
the presence of low (middle row) and high (bottom row) dose of  Actilide_Oc_1 (first 
and second column) or Inactilide_Oi_1 (third and fourth column) (supplemental 
material, Table S3). Markovian schemes of the simulated drug-channel interactions are 
depicted at the top. The orange arrows represent the transition rate that has been altered 
to simulate each mutation and the pink arrow indicates that the drug has a low affinity 
in that binding state.  
Figure 5. Experimental (top panels) [4] and simulated (bottom panels) steady-state 
activation (A and C) and deactivation time constants for WT (squares) and M54T 
hMiRP1 mutated (triangles) channels at 22ºC. Top panels are reprinted from [4] with 
permission from Elsevier. 
Figure 6. Simulated steady state AP of isolated endocardial cells (top row) and pseudo-
ECG (bottom row) for WT (black) and M54T hMiRP1 cells (orange) in the absence 
(left column) and in the presence of 16 nM (low dose) and 48 nM (high dose) of 
dofetilide (middle and right column, respectively). Inset of panel F shows the AP of 
midmyocardial cell #85 of the 1D model of the mutated transmural wedge preparation. 
Figure 7. Simulated steady state AP for endocardial WT (black) and M54T hMiRP1 
cells (orange) in the absence (thin) and in the presence (thick) of real (top row) and 
prototypical (bottom row) IKr activators under different conditions: in the presence of 
low dose (16nM) dofetilide (first column) and under IKr blocker drug free conditions 
(middle and last column). IKr activator dose is indicated in each panel. 
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Figure 8. Rate dependence of the effects of IKr mutants on ADP90 under drug-free 
conditions (black) and under exposure to low doses of those drugs that significantly 
amplify them, namely Actilide Oc_1 (red), Inactilide_Oi_1 (green) and Drug_C1 (blue) 
(supplemental material, Table S3). ADP90 differences between WT cells and mutated 
cells with altered IKr activation (A), deactivation (B), inactivation (C) and recovery from 
inactivation (D) producing a 50 ms (red) APD90 prolongation under drug-free conditions 
at 1 Hz. ADP90 differences between WT cells and mutated cells with altered IKr 
deactivation under exposure to low doses of Actilide Oc_1 (red) and Inactilide_Oi_1 
(green) at 2 Hz is not shown as mutated cells were stimulated before the repolarization 
process was completed. Markovian schemes of the simulated IKr mutants are depicted at 
the top. The orange arrows represent the transition rate that has been altered to simulate 
each mutation. 
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Table S1. Wild-Type (second column) and M54T hMiRP1 mutation (third column) transition 
rate constants. Tbase corresponds to 310 K. 
  
APD90 
prolongation 
Activation  
(αα factor) 
Deactivation 
( factor) 
Inactivation 
(αi factor) 
Recovery from 
inactivation 
(i factor) 
50 0.23 50 1.7 0.6 
20 0.41 23 1.25 0.81 
10 0.57 13 1.12 0.9 
 
Table S2. Scale factors in the rate constants used to simulate the concealed mutations (activation, 
deactivation, inactivation and recovery from inactivation, first, second, third and fourth column, 
respectively) depending on the observed APD90 prolongation (first column). 
  
 Name Low Dose 
(nM) 
Closed Open Inactivated 
k(µM-1s-1) r (s-1) k(µM-1s-1) r (s-1) k(µM-1s-1) r (s-1) 
B Drug_C1 10 0.511 0.003606     
Drug_C2 10 25.55 0.18030     
Drug_C3 10 51.1 0.3606     
C Drug_O1 10   0.511 0.003606   
Drug_O2 10   25.55 0.18030   
Drug_O3 10   51.1 0.3606   
D Drug_I1 10     0.511 0.003606 
Drug_I2 10     25.55 0.18030 
Drug_I3 10     51.1 0.3606 
E Actilide_Oc_1 3 0.511 3.606e-5 0.511 0.003606   
Actilide_Oc_2 290 0.511 0.003606 0.511 0.3606   
Actilide_ Oc_3 30 0.511 3.606e-4 0.511 0.03606   
Actilide_ Oc_4 30 0.511 3.606e-5 0.511 0.03606   
Actilide_Co 750 0.511 0.3606 0.511 0.003606   
F Dofetilide 16   0.511 0.016227 0.511 2.318 e-4 
Inactilide_Oi_1 3.6   0.511 0.003606 0.511 3.606e-5 
Inactilide_ Oi_2 340   0.511 0.3606 0.511 0.003606 
Inactilide_ Oi_3 35   0.511 0.03606 0.511 3.606e-4 
Inactilide_ Oi_4 35   0.511 0.03606 0.511 3.606e-5 
Inactilide_ Io 690   0.511 0.003606 0.511 0.3606 
 
Table S3. Kinetic rates of the simulated drug-IKr interactions. Markovian models (first 
column) are shown in Figure 2 and k and r are the association and dissociation rate 
constants, respectively.  
 
 
  
 Figure S1. Impact of IKr Markovian transition rates (top row) on IKr electrophysiology (left 
column) analyzed using a version of the sensitivity analysis proposed in [1]. Relative sensitivities 
of the electrophysiological properties of IKr (left column) to changes in its transition rates (top 
row) are represented using a gray color scale. White indicates that the transition rate (column) is 
the most influential transition rate for that current characteristic (row). Negative signs designate 
that the IKr property and the transition rate vary inversely. The sensitivity analysis was performed 
by multiplying or dividing by five one transition rate at a time. The increment of each IKr 
electrophysiological property was calculated as the difference between the value observed when 
the rate is five-folded and the value obtained when the rate is divided by five. Then, the relative 
sensitivity of a certain IKr electrophysiological property to a certain transition rate was calculated 
by dividing the corresponding increment by the maximum absolute value of the increments 
observed for that IKr property. Protocols are defined as in [2]. 
  
  
Figure S2. Simulated steady state AP (top row) and IKr (bottom row) and open state 
probability (bottom row) for endocardial WT (black) and mutated cells with altered IKr 
deactivation producing a 50 ms (red) APD90 prolongation under drug-free conditions 
(first column) and in the presence of 3 nM Actilide_Oc_1 (low dose, second column), 3.6 
nM Inactilide_Oi_1 (low dose, second column) and 10 nM Drug_C1 (low dose, forth 
column) (supplemental material, Table S3). Markovian schemes of the simulated drug-
channel interactions are depicted at the top. The orange arrows represent the transition 
rate that has been altered to simulate the deactivation mutation and the pink arrow 
indicates that the drug has a low affinity in that binding state.  
 
 
  
  
 
Figure S3. Simulated APD90 rate adaptation to abrupt changes in pacing frequency for 
endocardial WT (black) cells and mutants (red) with altered IKr activation (first row), 
deactivation (second row), inactivation (third row) and recovery from inactivation (fourth 
row) producing a 50 ms APD90 prolongation at 1Hz under drug-free conditions (left 
column) and in the presence of low doses of the types of drugs that most prolong the 
APD90 of each IKr mutated cell: 3 nM of Actilide_Oc_1 (first row), 10 nM Drug_C1 
(second row) or 3.6 nM of Inactilide_Oi_1 (third and fourth row) (supplemental material, 
Table S3). Drug_C1 is the drug that most prolongs the APD90 of the defective 
deactivation mutant without producing an AP longer than the basic cycle length at 1.7 
Hz. Time constants of the fast and slow phases of APD90 adaptation to accelerating and 
decelerating pacing rates are indicated in each panel. All mutants had shorter 
fast_decelerating than WT cells (18.6 s), with the activation mutant being the one that most 
shortens it (11.8 s) followed by the inactivation and recovery from inactivation mutants 
(13.7 s and 13.9 s, respectively). fast_accelerating was also prolonged by most mutations, 
although to a lesser extent. When WT cells and IKr mutants were exposed to the selected 
drugs, both slow time constants were prolonged, especially under Actilide_Oc_1 and 
Inactilide_Oi_1 exposure (second column and Table S4). The biggest differences 
between WT cells and IKr mutants on APD adaptation to abrupt changes in pacing rate 
under drug exposure were found in slow_decelarating and slow_accelarating when WT cells and 
activation IKr mutants were exposed to low dose of Inactilide_Oi_1. Indeed,slow_decelarating 
of WT cells and the activation IKr mutant was 114.7 s and 114.2 s under drug-free 
conditions and 71.4 s and 579 s after Inactilide_Oi_1 application, respectively, and  
slow_accelarating of WT cells and activation IKr mutants was 109.1 s and 114.6 s under drug-
free conditions and 97.6 s and 720.7 s after Inactilide_Oi_1 application. A dramatic 
increase on the difference in slow_accelarating between WT cells (109.1 s) and defective 
inactivation (115.2 s) and recovery from inactivation (109.5 s) mutants was also observed 
in the presence of Inactilide_Oi_1 (slow_accelarating = 97.6 s, 573.3 s and 581 s, 
respectively).  It is to be noted that negligible differences between the effects of Drug_C1 
and Drug_C2 on dynamics of APD rate adaptation of WT cells and IKr mutants were 
found (Table S4). 
 
  
 Drug-free Drug_C1 Drug_C2 Actilide_Oc_1 Inactilide_Io_1 
fast accelerating (s) 
WT 5.5 4.6 4.6 4.6 4.6 
Activation Mutant 4.8 3.3 3.3 2.9 3.8 
Deactivation Mutant 5.9 3.8 3.8   
Inactivation Mutant 5.1 3.9 3.9 3.9 3.9 
Recovery from Inactivation Mutant 5.2 3.9 3.9 3.9 4.0 
slow accelerating (s) 
WT 109.1 120.3 116.8 359.8 97.6 
Activation Mutant 114.6 121.3 121.4 357.7 720.7 
Deactivation Mutant 110.4 119.6 118.1   
Inactivation Mutant 115.2 115.1 119.5 402.6 573.3 
Recovery from Inactivation Mutant 109.5 116.8 120.8 402.9 581 
fast decelerating (s) 
WT 18.6 10.5 10.5 12.1 10.2 
Activation Mutant 11.8 7.1 7.1 7.0 7.7 
Deactivation Mutant 15.9 7.3 7.2   
Inactivation Mutant 13.7 8.0 8.0 9.3 7.4 
Recovery from Inactivation Mutant 13.9 8.1 8.1 9.4 7.5 
slow decelerating (s) 
WT 114.7 119.1 119.1 477.2 71.4 
Activation Mutant 114.2 122.7 123.2 351.8 579 
Deactivation Mutant 116 126.4 127.2   
Inactivation Mutant 114.9 126.6 125.1 515.8 119.6 
Recovery from Inactivation Mutant 114.5 123.6 122.6 510.2 119.0 
 
Table S4. Dynamics of APD adaptation to abrupt changes in pacing rate for endocardial  
WT cells and mutants with altered IKr activation, deactivation, inactivation and recovery 
from inactivation producing a 50 ms prolongation at 1 Hz (rows) under drug-free 
conditions and in the presence of selected drugs (columns) (Table S3). fast_accelerating, 
slow_accelerating, fast_decelerating and slow_decelerating are the time constant of the fast and the 
slow phase of the APD accommodation to the change in pacing rate from 1Hz to 1.7 Hz 
and from 1.7 Hz to 1 Hz, respectively. 
 
  
 
 
Figure S4. Simulated steady state AP for endocardial mutated cells with reduced IKs and 
increased INaL and in combination with altered IKr activation (first column), deactivation 
(second column), inactivation (third column) and recovery from inactivation (fourth 
column) under drug-free conditions in the presence of 3 nM (low dose) Actilide_Oc_1 
(first and second columns) or 3.6 nM (low dose) Inactilide_Io_1 (third and fourth 
column) (supplemental material, Table S3). Markovian schemes of the simulated IKr 
mutations are depicted at the top. The orange arrows represent the transition rate that has 
been altered to simulate each defective IKr. 
  
 
 IKr concealed mutants 
 Activation 
 
Deactivation 
 
Inactivation 
 
Recovery 
from 
inactivation 
Defective IKs 52 54 59 59 
Defective INaL 47 54 53 53 
Defective IKs + Drug_C1 55 120 69 69 
Defective INaL + Drug_C1 49 113 59 59 
 
Table S5. APD90 difference (ms) between WT and IKr activation, deactivation, inactivation 
and recovery from inactivation mutants (first, second, third and fourth column, respectively) 
combined with IKs or INaL silent mutations under drug-free conditions and under exposure 
to low dose of Drug_C1. 
  
  
Figure S5. Simulated pseudo-ECG for WT at 1 Hz in the presence of high dose of every 
drug considered in this study (see Table S3). Horizontal dashed lines indicate the baseline 
and vertical dashed lines highlight the instant 600 ms after the stimulation. 
  
 
Figure S6. Simulated pseudo-ECG (left) and APD along the 1D transmural wedge (right) 
for WT at 1 Hz in the presence high dose of certain drugs (see Table S3). Horizontal 
dashed lines indicate the baseline and vertical dashed lines highlight the instant 600 ms 
after the stimulation. 
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